Sofinnova Closes €82M Medtech Venture-Building Fund

Sofinnova has closed an €82 million venture-building fund dedicated to medical technology, with the round closing oversubscribed, according to a report by Dealroom.co.

The figure matters for two reasons. First, €82 million is a substantial pool for a strategy focused on building companies from scratch rather than backing existing startups. Second, the oversubscription signals that limited partners committed more capital than the fund's original target — a signal of investor demand for the medtech venture-building model at a time when broader life-science fundraising has grown more selective.

Venture building differs from conventional venture capital. Instead of writing checks into companies that already exist, the manager creates new companies in-house — sourcing the technology, recruiting founding teams and holding a large equity position from day one. Applied to medical technology, the model targets devices, diagnostics and digital health products with long regulatory paths, where control over company construction can shape outcomes.

The close extends Sofinnova's long-standing franchise in European and global life-science investing. The firm, one of Europe's most established names in the category, has historically deployed across pharmaceuticals, biotechnology and medical devices, and this vehicle narrows its focus squarely onto the medtech side of that mandate.

The oversubscribed result is the notable detail. Fund managers across venture capital have spent the past two years facing a harder fundraising environment, with many closing below target or extending timelines. An oversubscribed close in a specialized strategy such as medtech venture building runs against that current and indicates that allocators still see durable returns in building hardware-adjacent health companies rather than chasing software multiples.

The structure also concentrates risk and reward in a single portfolio construction method. By founding companies internally, the fund captures founder-level equity in each vehicle it launches — a costlier and more operationally demanding approach than traditional investing, but one that gives the manager control over assets from inception through exit.

What comes next is deployment. The €82 million will now go toward launching and scaling new medtech companies, and the pace and quality of those builds will test whether investor enthusiasm for the venture-building model translates into returns.